Abstract 201P
Background
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death worldwide. Since January 2020, Atezolizumab in combination with Bevacizumab has been the standard of care in 1st-line metastatic and locally advanced HCC, following data from the IMbrave 150 trial, which showed improved overall survival (OS) and low toxicity versus Nexavar. There are currently few real-life data on the use of this combination.
Methods
This is a retrospective study in 6 French centers, including patients treated with Atezolizumab and Bevacizumab for locally advanced and metastatic HCC. OS, progression-free-survival (PFS) and tolerability will be analyzed for the entire population, and according to WHO status and the type of underlying cirrhosis.
Results
Between February 2020 and October 2022, we included 70 patients with metastatic HCC. The median age was 70. Sixty-six patients (94%) were men. The majority had a WHO status of less than 2 (89%). Fifty-five patients (79%) had underlying cirrhosis, 75% non-viral, 15% viral and 10% mixed causes. Forty-seven patients (85%) had CHILD A cirrhosis. Prior to treatment initiation, 18 patients (33%) had esophageal varices. The median OS was 19months (IC 95%, 15-NE). The median PFS was 6.8months (IC95%, 4.7-14.2). The median OS was significantly better for patients had CHILS A cirrhosis compared CHILD B cirrhosis (p = 0.03). Five patients discontinued treatment due to toxicity. Thirty-seven percent of patients benefited from a second line of treatment at progression.
Conclusions
In this real-life study in a French population, Atezolizumab in combination with Bevacizumab was effective and well tolerated. Less than half the patients were able to receive 2nd-line treatment after progression. Updated analysis will be presented at the congress.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Moinard-Butot: Financial Interests, Personal and Institutional, Advisory Board: BMS. S. Husson Wetzel: Financial Interests, Personal, Other: Servier, BMS. M. Bolliet, P. Chiappa: Financial Interests, Personal, Other: MSD. C. Belletier: Financial Interests, Personal, Other: Servier, Viatris. C. Bigot: Financial Interests, Personal, Other: Servier. A. Abergel: Financial Interests, Personal, Invited Speaker: Gilead. M. Ben Abdelghani: Financial Interests, Personal, Invited Speaker: Incyte, Servier, Pierre Fabre; Financial Interests, Personal, Advisory Board: Merck, BMS, Bayer; Financial Interests, Institutional, Advisory Board: Deciphera. All other authors have declared no conflicts of interest.